Skip to content

NASDAQ · mid · thesis board

MRUS Merus

EGFR×LGR5 biclonics (petosemtamab)

View race

Thesis

Editorial summary — not a primary filing

Multispecific antibodies; petosemtamab expanding across head-neck and lung settings.

Next gate

2026-10-05Company-guidedPh2 readout

Expansion cohort data

53 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~15 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~517d)100%
Days to gate (53d)10%
Show math

$680M cash ÷ $40M/mo burn ≈ 517 days. Source: curated SEC quarter figures.

Cash $680M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokMRKApprovedokSMMTFiledok

Risks

  • Trial enrollment
  • Partner dynamics
  • Competitive ADCs/bispecifics
  • Burn rate

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03526835as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01